rAd-Rv2299c
rAd-Rv2299c is a chimpanzee adenovirus-vectored vaccine expressing Rv2299c. Constructed using pRSK17 shuttle plasmid, packaged in HEK293A cells, and purified by cesium chloride density centrifugation. Formulated for intranasal inhalation at 1×10⁸ PFU/50 μL PBS. The platform exhibits low human seroprevalence with trained immunity induction in DCs. No exogenous adjuvants.
Read MoreAd5-105K
The Inhaled Tuberculosis Vaccine (Adenovirus Type 5 Vector) developed by CanSino Biologics Inc. is a non-replicating viral-vectored vaccine intended for administration via nebulized inhalation by mouth. It is designed to induce both local mucosal immunity in the respiratory tract and systemic immune responses against Mycobacterium tuberculosis (Mtb). The adenovirus type 5 (Ad5) backbone functions as…
Read MoreTri:ChAd:TB
Tri:ChAd:TB is built on the chimpanzee adenovirus serotype 68 vector, expressing Ag85A, TB10.4, and RpfB. These antigens spanning distinct M.tb life-cycle stages. Ag85A wanes after acute infection, whereas TB10.4 remains highly expressed. RpfB is upregulated during dormancy and resuscitation. This vaccine is formulated for respiratory mucosal delivery.
Read MoreSeV986A
Our group utilizes an replication-defective Sendai virus (SeV) as TB vaccine vector, and constructed SeV85AB and SeV986A vaccine. SeV986A expressed a fusion of acute- and latency-stage Mtb antigens (4 antigens). In murine models, it serves as a potent BCG-booster, significantly reducing bacterial burden in both active and latent infection challenges.
Read MoreAd5Ag85A*
Ad5Ag85A is a human adenovirus serotype 5-vectored vaccine expressing Antigen 85A (Ag85A). This vaccine is delivered by the inhaled aerosol route.
Read More